GlassScriptPhysician profile
Jeffrey K Klotz
NPI 1659361855
$4,638.93
in general payments reported to CMS, 2019-2025
45 companies · $1,430 in 2025
The $1,430 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $933 · 2020: $68.91 · 2022: $51.72 · 2023: $705 · 2024: $1,450 · 2025: $1,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,463 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,463.15 |
| Education | $121.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $447.49 | 2019-2025 | |
| Celgene Corporation | $345.84 | 2023-2025 | Reblozyl, Opdualag, Opdivo |
| Novartis Pharmaceuticals Corporation | $333.18 | 2019-2025 | |
| Genentech USA, INC. | $302.97 | 2019-2025 | Alecensa, Tecentriq, Rozlytrek |
| Merck Sharp & Dohme LLC | $263.08 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Daiichi Sankyo INC. | $226.67 | 2024-2025 | Enhertu, Datroway |
| Eisai INC. | $191.50 | 2022-2025 | |
| Janssen Biotech, INC. | $169.23 | 2019-2025 | Rybrevant, Erleada |
| Alexion Pharmaceuticals, INC. | $164.27 | 2019 | |
| Servier Pharmaceuticals LLC | $161.44 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $152.45 | 2019-2025 | Opdivo |
| Gilead Sciences, INC. | $139.07 | 2019-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $130.63 | 2023-2025 | Ninlaro, Iclusig |
| Seagen INC. | $123.50 | 2019-2023 | Padcev |
| Jazz Pharmaceuticals INC. | $118.83 | 2023-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $114.88 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Exelixis INC. | $111.00 | 2019-2025 | Cabometyx |
| Sanofi-Aventis U.S. LLC | $99.95 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $86.14 | 2023-2025 | Libtayo |
| Amgen INC. | $82.61 | 2019-2023 | Lumakras |
| Incyte Corporation | $68.35 | 2023-2024 | Monjuvi |
| Astellas Pharma US INC | $65.87 | 2024-2025 | Xospata, Vyloy |
| Abbvie INC. | $65.47 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $62.77 | 2019-2024 | Tagrisso |
| Mirati Therapeutics, INC. | $60.48 | 2024 | Krazati |
| Glaxosmithkline, LLC. | $54.29 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Emd Serono, INC. | $53.48 | 2019-2025 | Bavencio |
| Sobi, INC | $52.13 | 2025 | |
| Genzyme Corporation | $36.88 | 2019 | |
| Tersera Therapeutics LLC | $35.98 | 2024-2025 | Xermelo, Zoladex |
| Pharmacyclics LLC, An Abbvie Company | $34.12 | 2019 | |
| Stemline Therapeutics INC. | $29.83 | 2025 | Orserdu |
| Beigene USA, INC. | $29.31 | 2024 | Brukinsa |
| Lexicon Pharmaceuticals, INC. | $24.43 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $22.00 | 2024 | Rybrevant |
| Bayer Healthcare Pharmaceuticals INC. | $21.97 | 2025 | |
| Aveo Pharmaceuticals, INC. | $19.93 | 2024 | |
| Puma Biotechnology, INC. | $19.84 | 2024 | |
| G1 Therapeutics, INC. | $18.66 | 2022 | |
| Novocure INC. | $18.03 | 2024 | Optune |
| Secura Bio, INC. | $17.10 | 2019 | |
| Deciphera Pharmaceuticals INC. | $16.78 | 2025 | Qinlock, Romvimza |
| Beone Medicines USA, INC. | $16.26 | 2025 | Brukinsa, Tevimbra |
| Csl Behring | $15.79 | 2019 | |
| Apo-Pharma USA, INC. | $14.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Klotz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.